long intergenic non-protein coding RNA 1848Genealiases: []
Q-omics provides the consensus-scored LINC01848 profile across patient tissues and cancer cell-line models. LINC01848 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01848 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, LINC01848 RNA expression shows 5,458 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, LUAD, and BRCA as cancer lineages where LINC01848 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01848 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01848 survival associations across molecular data types. LINC01848 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01848 RNA expression–survival associations across cancer types. High LINC01848 expression shows unfavorable associations in MESO, LUSC, STAD, PCPG and LAML, but favorable associations in LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01848 RNA expression.
This table summarizes LINC01848 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01848. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01848 shows higher tumor expression in LUAD, LIHC and LUSC. The LUAD box plot shows higher LINC01848 RNA expression in tumor versus normal tissue (log2 FC = +0.099, t-test p = .007).
This table shows molecular features associated with LINC01848 in patient tissues and cancer cell lines. In patient samples, LINC01848 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
